Figure 2. RALA outperforms commercial vectors for the delivery of pDNA encoding for CRISPR components.

The transfection of pDNA encoding for Cas9-T2A-GFP using RALA, Lipofectamine 3000, or PEI was characterized via flow cytometry. A) Transfection rate defined as the percentage of GFP⁺ cells in the transfected population. B) Cell viability defined as the total cell counts as a percentage of the non-transfected control count. C) Transfection yield defined as the percentage of GFP⁺ cells compared to the number of non-transfected control cells. The transfection was further characterized through D) representative fluorescent images of each transfection and E) the calculation of the cell doubling time from days 1 to 3. * denotes significance p<0.05 (n = 3), **p<0.01 (n = 3), ***p<0.001 (n = 3), ****p<0.0001 (n = 3).